OpGen Stock Gains On FDA Approval, Interim Q3 Sales

The FDA has granted 510(k) clearance to OpGen Inc's OPGN Acuitas AMR Gene Panel.
The Company is finalizing preparations for its commercial launch in the U.S. in Q4 of 2021.
The Acuitas AMR Gene Panel detects 28 genetic antimicrobial resistance (AMR) markers in isolated bacterial colonies from 26 different pathogens.
The Acuitas AMR Gene Panel expands the diagnostic capability of clinicians to rapidly and simultaneously test for select drugs in 9 classes of antibiotics.
Furthermore, the Company believes that the Acuitas AMR Gene Panel is the first FDA-cleared molecular diagnostic panel that detects a broad panel of AMR markers from isolates.
Also, OpGen reported interim Q3 revenue of approximately $1.2 million, up from $1.1 million a year ago.
Cash was approximately $25.4 million.
Related content: Benzinga's Full FDA Calendar.
Price Action: OPGN stock is up 26.1% at $3.48 during the premarket session on the last check Monday.

Earnings Calendar